Cassiopeia study myeloma
Web10 Dec 2024 · For example, the CASSIOPEIA study evaluated daratumumab, bortezomib, thalidomide, and dexamethasone (dara-VTd) vs VTd in newly diagnosed patients … WebThis study, conducted on behalf of the Intergroupe Francophone du Myelome (IFM) and Hemato-Oncologie voor Volwassenen Nederland (HOVON), was a phase III, randomized …
Cassiopeia study myeloma
Did you know?
Web24 Aug 2024 · Study design. This was an open-label, nonrandomized, multicenter, multiarm, phase 1b study in a large number of patients (N = 103). Treatment arms evaluated … WebIn a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induceda very good partial response or better rate of 42% and was well tolerated in …
Web22 Oct 2024 · Data from a subgroup analysis of CASSIOPEIA that were presented at the 17th International Myeloma Workshop also showcased an improvement in minimal residual disease (MRD) negativity rates and... WebThe Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, ... CASSIOPEIA (NCT02541383)CASSIOPEIA (NCT02541383) A Study to Evaluate Daratumumab in Transplant Eligible Participants With …
WebThe subgroup analysis for the type of myeloma evaluated IgG versus non-IgG disease and included patients with measurable disease in serum. A high-risk cytogenetic profile was … Web6 Jul 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma. Funding: The Intergroupe Francophone du Myélome and Dutch-Belgian …
Web28 Sep 2024 · CASSIOPEIA Part 2 Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma - The ASCO Post CASSIOPEIA Part 2: …
Webdiagnosed multiple myeloma, but overall survival results were mixed, and rates of second primary malignancies were increased compared with placebo or observation. Added value of this study. To our knowledge, part 2 of the CASSIOPEIA study is the first randomised controlled trial of daratumumab as maintenance daiwa crossfire reelWeb16 Mar 2024 · Multiple myeloma (MM) accounts for 15% of all hematologic malignancies, with an estimated 34,920 new cases in 2024 [1,2,3,4].The treatment approach to MM involves use of multidrug combinations and ... daiwa d carp pellet wagglerWebThe first part of the CASSIOPEIA study aimed to compare daratumumab (Dara), an anti-CD38 antibody, plus bortezomib (V), thalidomide (T), and dexamethasone (d) versusVTd alone in 1,085 transplant-eligible patients with newly diagnosed multiple myeloma. daiwa digital collegeWeb28 Dec 2024 · Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2024;394(10192):29-38. daiwa crossfire lt 2020Web5 Nov 2024 · APOLLO (NCT03180736) is a phase 3 study conducted in collaboration between European Myeloma Network investigators and Janssen to evaluate DARA SC … daiwa d carp feeder rodWeb28 May 2024 · Methods: CASSIOPEIA is a 2-part, randomized, open-label, phase 3 study in TE NDMM. Pts received 4 cycles ind and 2 cycles cons with D-VTd or VTd. 886 pts who … daiwa d turbo spincast comboWeb8 Apr 2024 · In regard to quadruplets, in the CASSIOPEIA study a significant benefit of Dara-VTD over VTD was not observed in HR group neither in term of sCR rate after consolidation nor in term of PFS. ... (UK-MRA Myeloma XV) study , which will enroll 1400 patients, treatment will be deescalated after ASCT in patients with MRD negativity … daiwa definition